(Circulation. 2000;101:805.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
From the Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo (K.I., M.Y., M.H., S.K., M.E., J.A., Y.-Q.L., N.S., K.T., Y.O.), and the Institute for Fundamental Research, Suntory Research Center, Suntory Ltd, Osaka (K.H., K.N.), Japan.
Correspondence to Yasuyoshi Ouchi, MD, PhD, Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail youchi-tky{at}umin.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe extracted the total polyphenolic fraction from red wine (RW-PF) by column chromatography. Treatment with RW-PF showed a potent inhibitory effect on the proliferation and DNA synthesis of cultured rat aortic smooth muscle cells (RASMCs). In contrast, the inhibitory effect of RW-PF on the proliferation of bovine carotid endothelial cells was observed only at much higher concentrations. To elucidate the molecular mechanisms of this antiproliferative effect of RW-PF on RASMCs, we investigated the effects of RW-PF on cell cycle regulation. RW-PF downregulated the expression of cyclin A mRNA and cyclin A promoter activity. In addition, RW-PF decreased the binding of nuclear proteins to the activating transcription factor (ATF) site in the cyclin A promoter and downregulated the mRNA levels of transcription factors, cAMP-responsive elementbinding protein (CREB), and ATF-1.
ConclusionsThese results suggest that the downregulation of cyclin A gene expression may contribute to the antiproliferative effect of red wine polyphenols on RASMCs through the inhibition of transcription factor expression.
Key Words: red wine polyphenol atherosclerosis smooth muscle cells
| Introduction |
|---|
|
|
|---|
LDL oxidation is known to be one of the initial events in atherogenesis,3 4 and the antioxidative effects of red wine polyphenols, which have been shown in vitro5 and in vivo,6 may be involved in the mechanism of the French paradox.7 Other aspects of atherogenesis are the dedifferentiation of vascular smooth muscle cells (VSMCs), their migration into the intima, and excessive proliferation of VSMCs in the neointima.8 Although VSMC proliferation plays an important role in the pathogenesis of atherosclerotic lesions, the effects of red wine polyphenols on VSMC proliferation in atherosclerotic lesions have not been elucidated.
Cyclin A is important in the G1/S transition and in the S and G2/M phases of the cell cycle and has a critical role in DNA replication.9 The cyclin A promoter contains activating transcription factor (ATF) or cAMP-responsive element (CRE), which are bound by cAMP-responsive elementbinding protein (CREB) and ATF-1 by heterodimer formation.10 The heterodimeric binding to the cyclin A ATF site is strongly related to the induction of maximal cyclin A gene expression.10
In this study, polyphenolic substances from red wine were extracted and the effects on proliferation of VSMCs compared with those of the vascular endothelial cells investigated.
| Methods |
|---|
|
|
|---|
|
Cell Culture
Rat aortic smooth muscle cells (RASMCs) were prepared from
Sprague-Dawley rats and cultured in Dulbeccos modified Eagles
medium supplemented with 10% FBS as described.14 Bovine
carotid endothelial cells (BCECs) were cultured in the
same medium without HEPES.14 Human aortic smooth muscle
cells (HASMCs) or human umbilical vein endothelial
cells (HUVECs) were cultured in Medium 199 (Earles salts, Nikken Bio
Medical Laboratory) or endothelial cell basal medium
(EBM, Bio Whittaker) supplemented with 10% FBS.15
Cell Proliferation and [3H]Thymidine
Incorporation
Cells were plated at a density of 10 000
cells/cm2 in 24-well plates. After 48 hours, the
cells were treated with RW-PF dissolved in 50% ethanol at final
concentrations of 1 to 100 µg/mL for 72 hours, and then cell number
was measured. For the thymidine incorporation study, cells were labeled
with [methyl-3H]thymidine at 1 µCi/mL during
the last 3 hours, and then thymidine incorporation was
measured.15 The effects of RW-PF on cell proliferation and
DNA synthesis were expressed as percentage of control containing 0.5%
ethanol as vehicle. Moreover, we examined thymidine incorporation into
RASMCs treated with 6 fractions (30 µg/mL) separated from RW-PF for
72 hours.
RNA Isolation and Northern Blot Analysis
Total RNA was extracted from the cells by guanidinium
isothiocyanate extraction and centrifugation through
cesium chloride.16 The cyclin A cDNA probes for each
species were amplified by reverse transcriptionpolymerase chain
reaction.17 RNA was fractionated on 1.3%
formaldehyde-agarose gel and transferred to nylon filters. The filters
were hybridized at 68°C for 2 hours with
32P-labeled cyclin A cDNA probe in QuikHyb
solution (Stratagene) and autoradiographed. The hybridized filters were
rewashed and rehybridized with 32P-labeled CREB
and ATF-1 cDNA probes.18 19 To confirm the equal loading
of RNA, the filters were rehybridized with a radiolabeled 18S rRNA
oligonucleotide probe.20
Transfection and Luciferase Assay
Reporter constructs containing a fragment of the human cyclin A
5'-flanking region (bp -266 to +205) were inserted into the
promoterless firefly luciferase reporter plasmid pGL2-Basic
(Promega).21 The normal ATF consensus sequence (TGACGTCA)
in the plasmid -266/+205 was mutated to TGCCCCCA by polymerase chain
reaction to generate the plasmid mut -266/+205.21 RASMCs
were transfected with 8 µg luciferase constructs by the DEAE-dextran
method followed by a 1-minute DMSO shock.14 BCECs were
also transfected with the same plasmids by a SuperFect transfection
reagent (QIAGEN Japan). To correct for variability in transfection
efficiency, we cotransfected 2 µg pRL-SV40 control plasmids.
Twenty-four hours after transfection, the cells were incubated with
RW-PF for 72 hours, and then 2 kinds of luciferase activity were
measured. The ratio of firefly luciferase activity to
Renilla luciferase activity in each sample was used as a
measure of normalized luciferase activity.
Gel Mobility Shift Assay
Nuclear extracts from RASMCs treated with RW-PF were
prepared.21 Protein concentrations were measured by the
Bio-Rad protein assay system based on the Bradford
method.21 A double-stranded
oligonucleotide probe synthesized according to the
sequence of the human cyclin A 5'-flanking region containing a typical
ATF site (bp -84 to -63; 5'-TGAATGACGTCAAGGCCGCGAG-3') was
radiolabeled.14 A binding reaction was performed at
room temperature for 20 minutes and analyzed by 5% native
polyacrylamide gel electrophoresis.15 To determine
the specificity of the DNA-proteinbinding complexes, a competition
assay using a 100-fold molar excess of unlabeled probe encoding the
wild-type ATF sequence or the mutated ATF sequence
(5'-TGAATGCCCCCAAGGCCGCGAG-3') was performed. The gel was
dried and autoradiographed at -80°C.
Cell DNA Staining
After 24 hours of incubation of RASMCs on chamber slides, RASMCs
were treated with RW-PF at the highest dose (100 µg/mL) for 12 hours.
As a positive control, RASMCs were treated with the antioxidant agent
pyrrolidine dithiocarbamate (PDTC; 100 µmol/L), which is known
to induce apoptosis in VSMCs22 for 12 hours. Cells
were washed and fixed with PBS containing 1%
glutaraldehyde for 30 minutes and then incubated in PBS
containing 10 µmol/L bisbenzimide (Hoechst 33258; Funakoshi Co)
for 15 minutes and examined under fluorescence microscopy.
Statistical Analysis
When statistically significant effects (P<0.05) were
found, the Newman-Keuls test (ANOVA) was used to isolate the
differences between groups. All data in the text and figures are
expressed as mean±SEM.
| Results |
|---|
|
|
|---|
Effects of RW-PF on Proliferation and DNA Synthesis
RW-PF significantly inhibited the growth of RASMCs and thymidine
incorporation into RASMCs in a concentration-dependent manner (Figure 2A
and 2B
). RW-PF decreased the cell
number of RASMCs to 94%, 93%, 87%, 77%, and 61% of control and
inhibited thymidine incorporation into RASMCs to 92%, 86%, 71%,
52%, and 18% of control at final concentrations of 1, 3, 10, 30, and
100 µg/mL, respectively. Differences between control medium
containing 0.5% ethanol and ethanol-free medium were not statistically
significant. These inhibitory effects of RW-PF on BCECs
were observed at much higher concentrations, especially at 100 µg/mL
(Figure 2C
and 2D
).
|
Effects of Six Fractions on DNA Synthesis in RASMCs
Six fractions (fractions 1 through 6) decreased thymidine
incorporation into RASMCs to 41%, 37%, 30%, 26%, 30%, and 22% of
control containing 0.15% ethanol as vehicle (Figure 3A
). The inhibitory effect of
each fraction was in proportion to its respective total polyphenolic
content (Figure 3B
).
|
Effects of RW-PF on Cyclin A Gene Expression
The expression of cyclin A mRNA in RASMCs was slightly decreased
at 4 hours after the addition of RW-PF (30 µg/mL) and was completely
suppressed at 48 to 72 hours (Figure 4A
).
Treatment with RW-PF for 72 hours significantly inhibited the cyclin A
mRNA to 80%, 43%, 16%, and 4% of control at final concentrations of
3, 10, 30, and 100 µg/mL, respectively (Figure 4B
). In
contrast, RW-PF did not inhibit cyclin A gene expression in BCECs,
except at a concentration of 100 µg/mL (Figure 4C
).
|
RW-PF decreased the transcriptional activity of the cyclin A
promoter in RASMCs to 87%, 71%, 69%, and 45% of control at final
concentrations of 3, 10, 30, and 100 µg/mL, respectively (Figure 5A
). The plasmid containing a mutated ATF
site in the cyclin A promoter had
12-fold lower luciferase activity
than that of the plasmid containing a normal ATF site. Luciferase
activity was not affected by RW-PF. In contrast, RW-PF did not inhibit
the cyclin A promoter activity in BCECs. (The transcriptional activity
was 96% and 103% of control at 10 and 30 µg/mL, respectively.)
|
In the gel mobility shift assay, specific binding of nuclear proteins
extracted from RASMCs to the ATF site was confirmed by addition of a
specific competitor (Figure 5B
, lanes 3 and 4). RW-PF decreased
the abundance of specific ATF-binding nuclear proteins in a
concentration-dependent manner (lanes 2 and 5 through 10). A supershift
assay using specific antibodies confirmed the existence of CREB and
ATF-1 in RASMC nuclear extracts (data not shown). After repeated
independent experiments, no difference was found between RASMCs in
ethanol-free medium (lane 2) and RASMCs with 0.5% ethanol (lane 5)
(data not shown).
Moreover, RW-PF downregulated the mRNA levels of the transcription
factors CREB and ATF-1, which are known to bind to the ATF site in the
cyclin A promoter with the same time course and
concentration-dependence as that of cyclin A mRNA (Figure 5C
).
Effects of RW-PF in Human Cells
RW-PF inhibited thymidine incorporation into HASMCs to 70% and
30% of control at 10 and 30 µg/mL (Figure 6A
) and downregulated the expression of
cyclin A mRNA in HASMCs in a concentration-dependent manner (Figure 6B
). In contrast, the inhibitory effects of RW-PF on
DNA synthesis and cyclin A gene expression in HUVECs were observed at
much higher concentrations, especially at 100 µg/mL (Figure 6C
and 6D
).
|
Examination of Apoptotic Cell Death
In the fluorescence microscope study after nucleic acid
staining, PDTC induced morphological changes indicative of
apoptotic cell death, such as condensation of chromatin and
shrinkage of the nucleus, in RASMCs (Figure 7C
). However, RW-PF even at the highest
concentration (100 µg/mL) did not cause any morphological changes in
RASMCs (Figure 7B
) compared with untreated RASMCs (Figure 7A
).
|
| Discussion |
|---|
|
|
|---|
RW-PF, the total polyphenolic fraction extracted from red wine,
contained a wide variety of polyphenols, including phenolic monomers
and polymers, which have different molecular weights. RW-PF was broadly
divided into 2 groups. One group, characterized by lower average
molecular weight, consisted of 4 fractions, fractions 1 through 4,
eluted first by 50% ethanol, and the other group, characterized by
higher average molecular weight, consisted of 2 fractions, fractions 5
and 6, eluted by 100% ethanol and 70% acetone, respectively. The
first 4 fractions (fractions 1 through 4) contained various
polyphenolic monomer components, such as anthocyanidins, catechins, and
flavonoids (unpublished data, K.N.). Although the percentage of each
monomer may be quite different among the 4 fractions, we have not found
any specific polyphenolic substance that is dominant in a specific
fraction. Fractions 5 and 6 contained a significant amount of specific
polyphenolic compounds, proanthocyanidins, which are polymerized
anthocyanidins (unpublished data, K.N.). In particular, fraction 6
contained almost 100% proanthocyanidins. The average molecular weights
of fractions 1 through 4 and fraction 6 (mainly proanthocyanidins) are
believed to be
200 to 400 and 1600 to 2000, respectively. It is
noteworthy that polyphenol fractions of different molecular weight
showed similar potent antiproliferative effects on VSMCs.
At present, there is no method for measuring concentrations of red
wine polyphenolic polymers in blood. However, Duthie et
al23 measured the concentration of polyphenolic monomers
after the intake of red wine by healthy volunteers and demonstrated
that the intake of 100 mL red wine resulted in an increase in plasma
concentration of 2.5 µg/mL (gallic acid equivalents). This
observation suggests that the absorption efficiency of red wine
polyphenolic monomers is
5%. If polyphenolic polymers were also
absorbed through the intestine at the same level of absorption
efficiency, the final blood concentration after an intake of 100 mL red
wine would be
3.2 µg/mL. Thus, it may be reasonable to suppose
that the physiological concentration of RW-PF in
blood after a normal intake of red wine may be 1 to 10 µg/mL. It can
be assumed that the long-term (years) effect of even lower
concentrations of RW-PF may have an inhibitory effect on
VSMC growth in vivo.
Red wine polyphenols have been shown to have antioxidative effects in terms of LDL oxidation in vitro.5 Moreover, recent in vivo studies have shown that red wine polyphenols contribute to the inhibition of LDL oxidation in healthy volunteers6 and in apolipoprotein E knockout mice.24 Although antioxidant agents are reported to induce apoptosis in VSMCs,22 despite prolonged treatment of RASMCs with RW-PF, we did not observe any evidence of apoptosis. We suggest that the inhibitory effects of RW-PF on RASMCs may not be mediated by an apoptotic process.
It was recently been reported that resveratrol, a polyphenolic compound, is an agonist for the estrogen receptor.25 The agent is similar in structure to synthetic estrogen-like compounds. Estrogen, which is a ligand for the estrogen receptor expressed in VSMCs, has been shown to have an antiatherogenic effect by inhibiting the proliferation of VSMCs.26 27 This estrogen-like agonistic function of resveratrol is one possible explanation for the antiproliferative effects of RW-PF on VSMCs.
In regard to the downregulation of the cyclin A gene, it has been demonstrated that in mink lung epithelial cells, transforming growth factor-ß1 treatment decreased cyclin A mRNA and promoter activity but not the abundance of the ATF-binding proteins CREB and ATF-1 at 24 hours.10 In a study using vascular endothelial cells, contact inhibition decreased the level of cyclin A mRNA almost completely; however, the level of ATF-1 mRNA was partially decreased and that of CREB mRNA was not changed.28 In the present study, RW-PF treatment completely decreased the levels of CREB and ATF-1 mRNA. It has been shown that CREB promoter contains the ATF/CRE site, which might be regulated by CRE-binding proteins, including CREB itself.29 Because transcription of the CREB gene may be controlled by positive autoregulation through the ATF/CRE site, it can be postulated that RW-PF may downregulate the transcription of CREB gene through some unknown mechanism first and may start to decrease the cyclin A promoter activity. The downregulation of CREB may also act on the ATF/CRE site of its promoter, and finally, CREB may become completely downregulated. The same might be true for the regulation of the ATF-1 gene.
Taken together, red wine polyphenols had potent antiproliferative effects on VSMCs, and these inhibitory effects may be associated with the downregulation of cyclin A gene expression through the inhibition of transcription factor expression. Our findings suggest that the antiproliferative effect of RW-PF may be one possible mechanism for the antiatherogenic effects of red wine, other than the antioxidative effects of red wine polyphenols on LDL. Furthermore, elucidation of the mechanisms of downregulation of cell cyclerelated factors will provide important insights into the antiproliferative effects of red wine polyphenols on VSMCs.
| Acknowledgments |
|---|
Received March 26, 1999; revision received August 5, 1999; accepted August 26, 1999.
| References |
|---|
|
|
|---|
2. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1979;1:10171020.[Medline] [Order article via Infotrieve]
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915924.[Medline] [Order article via Infotrieve]
4. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 1993;98:19.[Medline] [Order article via Infotrieve]
5. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet. 1993;341:454457.[Medline] [Order article via Infotrieve]
6. Kondo K, Matsumoto A, Kurata H, Tanahashi H, Koda H, Amachi T, Itakura H. Inhibition of oxidation of low-density lipoprotein with red wine. Lancet. 1994;344:1152.[Medline] [Order article via Infotrieve]
7. Inhibition of LDL oxidation by phenolic substances in red wine: a clue to the French paradox? Nutr Rev.. 1993;51:185187.[Medline] [Order article via Infotrieve]
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801809.[Medline] [Order article via Infotrieve]
9. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991;67:11691179.[Medline] [Order article via Infotrieve]
10.
Yoshizumi M, Wang H, Hsieh CM, Sibinga NE, Perrella MA,
Lee ME. Down-regulation of the cyclin A promoter by transforming growth
factor-beta1 is associated with a reduction in
phosphorylated activating transcription factor-1 and
cyclic AMP-responsive element-binding protein. J Biol
Chem. 1997;272:2225922264.
11.
Folin O, Denis W. On phosphotungstic-phosphomolybdic
compounds as color reagents. J Biol Chem. 1912;12:239243.
12. Swain T, Hillis WE. The phenolic constituents of Prunus domestica, 1: the quantitative analysis of phenolic constituents. J Sci Food Agric. 1959;10:6368.
13. Bate-Smith EC. Phytochemistry of proanthocyanidins. Phytochemistry. 1975;14:11071113.
14.
Lee ME, Bloch KD, Clifford JA, Quertermous T.
Functional analysis of the endothelin-1 gene promoter: evidence
for an endothelial cell-specific cis-acting sequence.
J Biol Chem. 1990;265:1044610450.
15. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146153.[Medline] [Order article via Infotrieve]
16.
Perrella MA, Yoshizumi M, Fen Z, Tsai JC, Hsieh CM,
Kourembanas S, Lee ME. Transforming growth factor-beta 1, but not
dexamethasone, down-regulates nitric-oxide synthase mRNA
after its induction by interleukin-1 beta in rat smooth muscle cells.
J Biol Chem. 1994;269:1459514600.
17.
Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM,
Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell
growth by homocysteine: a link to atherosclerosis.
Proc Natl Acad Sci U S A. 1994;91:63696373.
18. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989;59:675680.[Medline] [Order article via Infotrieve]
19.
Hai TW, Liu F, Coukos WJ, Green MR. Transcription
factor ATF cDNA clones: an extensive family of leucine zipper proteins
able to selectively form DNA-binding heterodimers. Genes
Dev. 1989;3:20832090.
20.
Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP,
Quertermous T, Lee ME. Tumor necrosis factor increases transcription of
the heparin-binding epidermal growth factor-like growth factor gene in
vascular endothelial cells. J Biol
Chem. 1992;267:94679469.
21. Yoshizumi M, Lee WS, Hsieh CM, Tsai JC, Li J, Perrella MA, Patterson C, Endege WO, Schlegel R, Lee ME. Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 1995;95:22752280.
22.
Tsai JC, Jain M, Hsieh CM, Lee WS, Yoshizumi M,
Patterson C, Perrella MA, Cooke C, Wang H, Haber E, Schlegel R, Lee ME.
Induction of apoptosis by pyrrolidinedithiocarbamate and
N-acetylcysteine in vascular smooth muscle cells. J Biol
Chem. 1996;271:36673670.
23. Duthie GG, Pedersen MW, Gardner PT, Morrice PC, Jenkinson AM, McPhail DB, Steele GM. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. Eur J Clin Nutr. 1998;52:733736.[Medline] [Order article via Infotrieve]
24.
Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P,
Coleman R, Elis A, Aviram M. Reduced progression of
atherosclerosis in apolipoprotein E-deficient mice
following consumption of red wine, or its polyphenols quercetin or
catechin, is associated with reduced susceptibility of LDL to oxidation
and aggregation. Arterioscler Thromb Vasc Biol. 1997;17:27442752.
25.
Gehm BD, McAndrews JM, Chien PY, Jameson JL.
Resveratrol, a polyphenolic compound found in grapes and wine, is an
agonist for the estrogen receptor. Proc Natl Acad Sci
U S A. 1997;94:1413814143.
26. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H. Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis. 1997;130:110.[Medline] [Order article via Infotrieve]
27.
Morey AK, Pedram A, Razandi M, Prins BA, Hu RM,
Biesiada E, Levin ER. Estrogen and progesterone inhibit vascular smooth
muscle proliferation. Endocrinology. 1997;138:33303339.
28. Yoshizumi M, Hsieh CM, Zhou F, Tsai JC, Patterson C, Perrella MA, Lee ME. The ATF site mediates downregulation of the cyclin A gene during contact inhibition in vascular endothelial cells. Mol Cell Biol. 1995;15:32663272.[Abstract]
29. Walker WH, Fucci L, Habener JF. Expression of the gene encoding transcription factor cyclic adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB): regulation by follicle-stimulating hormone-induced cAMP signaling in primary rat Sertoli cells. Endocrinology. 1995;136:35343545.[Abstract]
This article has been cited by other articles:
![]() |
R. Gul, J.-H. Park, S.-Y. Kim, K. Y. Jang, J.-K. Chae, J.-K. Ko, and U.-H. Kim Inhibition of ADP-ribosyl cyclase attenuates angiotensin II-induced cardiac hypertrophy Cardiovasc Res, February 15, 2009; 81(3): 582 - 591. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Janszky, R. Ljung, S. Ahnve, J. Hallqvist, A. M. Bennet, and K. J. Mukamal Alcohol and long-term prognosis after a first acute myocardial infarction: the SHEEP study Eur. Heart J., January 1, 2008; 29(1): 45 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lefevre, S.-E. Michaud, P. Haddad, S. Dussault, C. Menard, J. Groleau, J. Turgeon, and A. Rivard Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide FASEB J, December 1, 2007; 21(14): 3845 - 3852. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Anselm, M. Chataigneau, M. Ndiaye, T. Chataigneau, and V. B. Schini-Kerth Grape juice causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of eNOS Cardiovasc Res, January 15, 2007; 73(2): 404 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Conover, L. K. Bale, S. C. Harrington, Z. T. Resch, M. T. Overgaard, and C. Oxvig Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol Am J Physiol Cell Physiol, January 1, 2006; 290(1): C183 - C188. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Diebolt, L. Germain, F. A. Auger, and R. Andriantsitohaina Mechanism of potentiation by polyphenols of contraction in human vein-engineered media Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2918 - H2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Szmitko and S. Verma Antiatherogenic potential of red wine: clinician update Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2023 - H2030. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Janszky, M Ericson, M Blom, A Georgiades, J-O Magnusson, H Alinagizadeh, and S Ahnve Wine drinking is associated with increased heart rate variability in women with coronary heart disease Heart, March 1, 2005; 91(3): 314 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dell'Agli, A. Busciala, and E. Bosisio Vascular effects of wine polyphenols Cardiovasc Res, September 1, 2004; 63(4): 593 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Waddington, I. B Puddey, and K. D Croft Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation Am. J. Clinical Nutrition, January 1, 2004; 79(1): 54 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stocker and R. A O'Halloran Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall Am. J. Clinical Nutrition, January 1, 2004; 79(1): 123 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pellegatta, A. A. Bertelli, B. Staels, C. Duhem, A. Fulgenzi, and M. E. Ferrero Different short- and long-term effects of resveratrol on nuclear factor-{kappa}B phosphorylation and nuclear appearance in human endothelial cells Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1220 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Briviba, L. Pan, and G. Rechkemmer Red Wine Polyphenols Inhibit the Growth of Colon Carcinoma Cells and Modulate the Activation Pattern of Mitogen-Activated Protein Kinases J. Nutr., September 1, 2002; 132(9): 2814 - 2818. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iijima, M. Yoshizumi, M. Hashimoto, M. Akishita, K. Kozaki, J. Ako, T. Watanabe, Y. Ohike, B. Son, J. Yu, et al. Red Wine Polyphenols Inhibit Vascular Smooth Muscle Cell Migration Through Two Distinct Signaling Pathways Circulation, May 21, 2002; 105(20): 2404 - 2410. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Bernatova, O. Pechanova, P. Babal, S. Kysela, S. Stvrtina, and R. Andriantsitohaina Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H942 - H948. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Watanabe, M. Yoshizumi, M. Akishita, M. Eto, K. Toba, M. Hashimoto, K. Nagano, Y.-Q. Liang, Y. Ohike, K. Iijima, et al. Induction of Nuclear Orphan Receptor NGFI-B Gene and Apoptosis in Rat Vascular Smooth Muscle Cells Treated With Pyrrolidinedithiocarbamate Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1738 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bentzon, E. Skovenborg, C. Hansen, J. Moller, N. S.-C. de Gaulejac, J. Proch, and E. Falk Red Wine Does Not Reduce Mature Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, March 27, 2001; 103(12): 1681 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Blanco-Colio, M. Valderrama, L. A. Alvarez-Sala, C. Bustos, M. Ortego, M. A. Hernandez-Presa, P. Cancelas, J. Gomez-Gerique, J. Millan, and J. Egido Red Wine Intake Prevents Nuclear Factor-{kappa}B Activation in Peripheral Blood Mononuclear Cells of Healthy Volunteers During Postprandial Lipemia Circulation, August 29, 2000; 102(9): 1020 - 1026. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |